Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data
13 August 2024 - 4:50PM
AllPennyStocks.com
A California-based biotech company is finding
early success on Tuesday after the company announced positive
preliminary data of Vebreltinib in patients with non-CNS met
fusion...
To read the full story on AllPennyStocks.com, click
here.
Apollomics (NASDAQ:APLMW)
Historical Stock Chart
Von Jan 2025 bis Feb 2025
Apollomics (NASDAQ:APLMW)
Historical Stock Chart
Von Feb 2024 bis Feb 2025